Compare Fox Corp Class B (FOX) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Moderna, Inc. — how do they compare? Fox Corp Class B trades at $56.88 (market cap $24.97B), while Moderna, Inc. trades at $196.72 (market cap $78.44B). The key difference: Moderna, Inc. is far larger — about 3.1× Fox Corp Class B's market cap, and Fox Corp Class B pays a 1.04% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Moderna, Inc. for 59 Days on average.
| FOX | MRNA | |
|---|---|---|
Market Cap | $24.97B | $78.44B |
Volume | 643,221 | 14,597,511 |
Sector | Media | Health |
52-Week High | $67.76 | $203.46 |
52-Week Low | $44.39 | $22.36 |
Typical Hold Time | 75 Days | 59 Days |
Enterprise Value | $28.33B | $74.59B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $56.97, up 2.5% today, with a bearish technical signal but strong fundamentals including a P/E of 14.59 and net income margin of 9.84%. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight operational strength, while cash flow improved to $1.03B in 2025. The stock faces resistance near $57 with support at $55.
The outlook is mixed: analyst consensus targets $84.75 (49% upside) with 42% buy ratings, but technical indicators and projected 2026 earnings decline pose risks. Key opportunities include valuation discount and dividend yield; risks involve earnings volatility and competitive pressures in media.
Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.
Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
